Tandem Diabetes Care (TNDM) Could Be 23% Below Fair Value After Q2 Results
Tandem Diabetes Care has seen a significant share price increase following strong second-quarter 2026 results that featured record sales and improved margins. Analysts suggest the company may still be undervalued despite recent gains, driven by growth in pharmacy-based supply sales.
Tandem Diabetes Care (TNDM) Could Be 23% Below Fair Value After Q2 Results Tandem Diabetes Care (TNDM) Could Be 23% Below Fair Value After Q2 Results · Simply Wall St. Simply Wall St Sat, 8 August 2026 at 10:07 pm GMT-4 2 min read TNDM +19.11% Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide.
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in